Umbralisib - TG Therapeutics
Alternative Names: RP 5307; RP-5264; TGR-1202; UKONIQLatest Information Update: 28 Jul 2024
At a glance
- Originator Incozen Therapeutics; Rhizen Pharmaceuticals
- Developer TG Therapeutics Inc; Vanderbilt-Ingram Cancer Center
- Class Amines; Antineoplastics; Benzopyrans; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Casein kinase 1 epsilon inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic lymphocytic leukaemia
- Phase II/III Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Phase II Hodgkin's disease; Waldenstrom's macroglobulinaemia
- Phase I/II Non-Hodgkin's lymphoma
- No development reported Multiple sclerosis; Myelofibrosis; Polycythaemia vera; Richter's syndrome; Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Polycythaemia-vera(Combination therapy) in USA (PO)
- 03 Jul 2024 TG Therapeutics terminates phase II trial in Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater) in USA (PO) due to strategic/business decision (NCT02742090)
- 31 May 2024 TG Therapeutics completes a phase I clinical trials in Polycythaemia vera (Combination therapy) in USA (PO) (NCT02493530)